Renaissance Technologies LLC Cuts Stock Holdings in Kamada Ltd. (NASDAQ:KMDA)

Renaissance Technologies LLC reduced its stake in Kamada Ltd. (NASDAQ:KMDA) by 1.3% during the second quarter, according to its most recent filing with the SEC. The fund owned 836,305 shares of the biotechnology company’s stock after selling 11,100 shares during the quarter. Renaissance Technologies LLC owned 1.45% of Kamada worth $4,148,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Aristides Capital LLC boosted its holdings in shares of Kamada by 41.6% in the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after buying an additional 16,635 shares during the last quarter. Y.D. More Investments Ltd boosted its holdings in shares of Kamada by 1,956.0% in the 2nd quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock worth $3,643,000 after buying an additional 690,842 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Kamada by 8.2% in the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after buying an additional 100,800 shares during the last quarter. 20.38% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on KMDA shares. Stifel Nicolaus started coverage on shares of Kamada in a report on Wednesday, July 3rd. They set a “buy” rating and a $18.00 price objective on the stock. StockNews.com downgraded shares of Kamada from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Kamada in a report on Thursday, August 15th.

Kamada Stock Up 0.7 %

NASDAQ KMDA opened at $5.41 on Friday. The company has a market cap of $310.97 million, a PE ratio of 23.52 and a beta of 1.07. Kamada Ltd. has a 52 week low of $4.08 and a 52 week high of $6.53. The firm’s 50-day simple moving average is $5.52 and its two-hundred day simple moving average is $5.44.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.02. Kamada had a return on equity of 6.15% and a net margin of 9.75%. The firm had revenue of $42.47 million for the quarter, compared to analysts’ expectations of $39.70 million. As a group, equities research analysts anticipate that Kamada Ltd. will post 0.26 EPS for the current year.

Kamada Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.